Icotinib

small molecule

Identifier: CI-DRUG-00000292
Entity page: /drug/icotinib ↗
Edges: 102

Neighbours: 21 cancers1 genes3 variants10 trials
Drawn: 35 of 35 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Icotinib predicts response to …PREDICTS_RESPONSE_TO3 of 3
← predicts response to	EGFR Fusionfusion	resistance	C	Lung Adenocarcinoma	1	Curated	civic	graph →
← predicts response to	EGFR T790MSNV	resistance	C

Icotinib targets …TARGETS1 of 1
→ targets	EGFR	—	INHIBITOR	—	1	Curated	chembl	graph →

Icotinib targets …TARGETS1 of 1

→ targets

EGFR

—

INHIBITOR

—

Curated

Icotinib investigated for …INVESTIGATED_FOR11 of 11
→ investigated for	Lung Adenocarcinomasubtype 2 source records aggregated	supports	C	Lung Adenocarcinoma	2	Curated	civic	graph →
→ investigated for	Lung Neoplasmcancer_family	unknown	3	Lung Neoplasm	1	Curated	chembl	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype	unknown	3	Lung Non-Small Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Neoplasmcancer_family	unknown	3	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Nasopharyngeal Carcinomasubtype	unknown	2	Nasopharyngeal Carcinoma	1	Curated	chembl	graph →
→ investigated for	Breast Neoplasmcancer_family	unknown	2	Breast Neoplasm	1	Curated	chembl	graph →
→ investigated for	Esophageal Neoplasmcancer_family	unknown	2	Esophageal Neoplasm	1	Curated	chembl	graph →
→ investigated for	Squamous Cell Carcinomahistology	unknown	2	Squamous Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Carcinomacancer_family	unknown	2	Carcinoma	1	Curated	chembl	graph →
→ investigated for	Lung Adenocarcinomasubtype	unknown	2	Lung Adenocarcinoma	1	Curated	chembl	graph →
→ investigated for	Pancreatic Neoplasmsubtype	unknown	1	Pancreatic Neoplasm	1	Curated	chembl	graph →

Icotinib investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 21show all (up to 200)
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 40 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	40	Observed	clinicaltrials	graph →
→ investigated in trials for	Brain Neoplasm 6 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Brain Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Adenocarcinoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Adenocarcinomasubtype 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Neoplasmcancer_family 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Squamous Cell Carcinoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Squamous Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Lung Neoplasm 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Lung Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasm 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Pancreatic Neoplasm 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Pancreatic Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Nasopharyngeal Carcinomasubtype 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Nasopharyngeal Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Solid Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Esophageal Carcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Esophageal Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Esophageal Squamous Cell Carcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Esophageal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Gastroesophageal Junction Adenocarcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Gastroesophageal Junction Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Carcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Carcinoma	1	Observed	clinicaltrials	graph →

Icotinib studied in …STUDIED_INderived10 of 66show all (up to 200)
→ studied in	NCT07806604recruiting Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer · 66 trials list this drug (5 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05263947Phase 2 · completed Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation · 66 trials list this drug (5 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04206072Phase 2/Phase 3 · completed D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC · 66 trials list this drug (5 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06955325Phase 3 · not yet recruiting Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations · 66 trials list this drug (5 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02264210Phase 2 · completed Icotinib for Completed Resected IB NSCLC With EGFR Mutation · 66 trials list this drug (5 active)	—	—	Lung Neoplasm,Lung Large Cell Carcinoma,Lung Non-Small Cell Carcinoma+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT05007938Phase 2 · unknown Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer · 66 trials list this drug (5 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06517953Phase 2 · recruiting Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations · 66 trials list this drug (5 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT01973725Phase 2 · completed Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy · 66 trials list this drug (5 active)	—	—	Esophageal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05514314Phase 2 · unknown A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection · 66 trials list this drug (5 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02044328Phase 2 · completed Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation · 66 trials list this drug (5 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths